Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy

monitoring of immune checkpoints, immune cell death, immune suppressive cells and T-cell polarisation

monitoring of immune checkpoints, immune cell death, immune suppressive cells and T-cell polarisation

Time frame: up to 12 months after the end of radiochemotherapy

Progression free survival

time interval between the date of initiation of treatment and the date of first progression (local, remote \[extent of the disease by RECIST v1.1\] second cancer) or death from any cause

Time frame: date of first progression of the disease (within 2 year after the initiation of the treatment)]

overall survival

time between the date of initiation of treatment and the date of death from any cause

Time frame: date of death from any cause (within 2 years after the initiation of the treatment)

Quality of life related to health measured by EORTC-QLQC30

Quality of life related to health measured by EORTC-QLQC30

Time frame: from the inclusion to patient death, up to 1 year